1. Home
  2. QCLS vs HCWB Comparison

QCLS vs HCWB Comparison

Compare QCLS & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Q/C Technologies Inc.

QCLS

Q/C Technologies Inc.

N/A

Current Price

$0.43

Market Cap

3.7M

Sector

Health Care

ML Signal

N/A

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

N/A

Current Price

$1.10

Market Cap

3.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QCLS
HCWB
Founded
2014
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7M
3.6M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
QCLS
HCWB
Price
$0.43
$1.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 184.3K
86.0K
Earning Date
11-18-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 22.33
N/A
EPS
★ N/A
N/A
Revenue
$3,929,527.00
★ $4,099,750.00
Revenue This Year
N/A
$12,215.61
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 32.71
N/A
52 Week Low
$0.42
$0.86
52 Week High
$8.17
$23.94

Technical Indicators

Market Signals
Indicator
QCLS
HCWB
Relative Strength Index (RSI) 26.07 32.80
Support Level $0.42 $1.12
Resistance Level $1.18 $1.73
Average True Range (ATR) 0.05 0.09
MACD 0.04 0.04
Stochastic Oscillator 7.71 13.89

Price Performance

Historical Comparison
QCLS
HCWB

About QCLS Q/C Technologies Inc.

Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

Share on Social Networks: